Mitogen-activated protein kinase (MAPK) phosphatase-3 (MKP-3) displays a p-JNK-MAPK substrate preference in

Christian Ndong1, Russell P Landry2, Madhurima Saha2

  • 1Geisel School of Medicine at Dartmouth, Department of Anesthesiology, Lebanon, NH, USA; Thayer School of Engineering at Dartmouth, Hanover, NH, USA.

Insights

Mitogen-activated protein kinase phosphatase-3 (MKP-3) preferentially dephosphorylates JNK in astrocytes, modulating their immune response. This suggests MKP-3 induction could treat neurological disorders involving astrocytes.

Area of Science:

  • Neuroimmunology
  • Molecular Cell Biology

Background:

  • Mitogen-activated protein kinases (MAPKs) are crucial for central nervous system immune responses mediated by glial cells.
  • MAPK activity is regulated by MAPK phosphatases (MKPs), with MKP-3 known to preferentially dephosphorylate p-ERK over p-JNK and p-p38.
  • Astrocytes exhibit a JNK>ERK activity profile under stress, suggesting potential tissue-specific substrate preferences for MKP-3.

Purpose of the Study:

  • To investigate the substrate preference of MKP-3 in primary rat astrocytes.
  • To determine if MKP-3 exhibits differential activity towards JNK and ERK in astrocytes.
  • To explore the potential of MKP-3 modulation for treating neurological conditions.

Main Methods:

  • Primary rat neonatal brain cortex astrocytes were transfected to express MKP-3.
  • Cells were stimulated with lipopolysaccharide (LPS).
  • MAPK phosphorylation (p-ERK, p-p38, p-JNK), nitric oxide (NO), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNFα) were analyzed via Western blot and ELISA.

Main Results:

  • MKP-3 expression significantly reduced LPS-induced p-ERK (~50%) and p-p38 (~50%), and markedly reduced p-JNK (~75%) in astrocytes.
  • MKP-3 moderately decreased NO production and completely blocked IL-6 and TNFα release.
  • Data confirmed MKP-3 preferentially dephosphorylates p-JNK over p-ERK in astrocytes, indicating differential substrate preference compared to other cell types.

Conclusions:

  • MKP-3 exhibits a distinct substrate preference in astrocytes, primarily targeting p-JNK.
  • Modulating astrocytic immune functions via MKP-3 induction offers a potential therapeutic strategy for neurological disorders.
  • This approach may be particularly beneficial for conditions like persistent pain where astrocytes play a significant role.